Validation of the International Myeloma Working Group standard response criteria in the PETHEMA/GEM2012MENOS65 study: are these times of change?

Blood. 2021 Nov 11;138(19):1901-1905. doi: 10.1182/blood.2021012319.
No abstract available

Publication types

  • Clinical Trial, Phase III
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bortezomib / therapeutic use
  • Dexamethasone / therapeutic use
  • Humans
  • Induction Chemotherapy
  • Lenalidomide / therapeutic use
  • Multiple Myeloma / diagnosis*
  • Multiple Myeloma / therapy*
  • Prognosis
  • Progression-Free Survival
  • Stem Cell Transplantation*
  • Transplantation, Autologous
  • Treatment Outcome

Substances

  • Bortezomib
  • Dexamethasone
  • Lenalidomide